MRX-2843 is under clinical development by Meryx and currently in Phase I for Refractory Acute Myeloid Leukemia. According to GlobalData, Phase I drugs for Refractory Acute Myeloid Leukemia have a 69% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how MRX-2843’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

MRX-2843 overview

MRX-2843 is under development for the treatment of relapsed/refractory acute myeloid leukemia, acute lymphoblastic leukemia, solid tumors including  melanoma, breast cancer, glioblastoma and non-small cell lung cancer. It is administered orally as a tablet and capsule. The drug candidate acts by targeting of Mer tyrosine kinase and Fms-like tyrosine kinase 3 (FLT3).

Meryx overview

Meryx., a developer of mer tyrosine kinase inhibitor therapeutics for cancer. The company is headquartered in United States.

For a complete picture of MRX-2843’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.